As of November 10, 2026, 7 holders' latest Schedule 13D or 13G filings report owning 5% or more of Sutro Biopharma, Inc. The largest reported stake is Perceptive Advisors LLC's, at 7.9%. 19 filings are on record since July 16, 2025 (Schedule 13G/A, August 14, 2026).
Sell to companies like Sutro Biopharma, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Coastlands Capital LP · Sole voting: 0 · Shared voting: 852,669 · Sole dispositive: 0 · Shared dispositive: 852,669 · SCHEDULE 13G, 2026-11-09
- · Reporting person: Perceptive Advisors LLC · Sole voting: 0 · Shared voting: 1,304,846 · Sole dispositive: 0 · Shared dispositive: 1,304,846 · SCHEDULE 13G/A, 2026-08-14
- · Reporting person: Point72 Asset Management, L.P. · Sole voting: 0 · Shared voting: 237,827 · Sole dispositive: 0 · Shared dispositive: 237,827 · SCHEDULE 13G/A, 2026-08-14
- · Reporting person: BlackRock, Inc. · Sole voting: 1,052,565 · Shared voting: 0 · Sole dispositive: 1,065,366 · Shared dispositive: 0 · SCHEDULE 13G, 2026-07-30
- · Holder: Srinivas Akkaraju · Percent: 6.4% · SCHEDULE 13G
Sutro Biopharma, Inc. has 19 Schedule 13D or 13G filings on record since 2025-07-16. 7 holders' latest filing reports 5% or more of common stock, par value $0.001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Layoffs on record: 1 filing or notice, latest 2025-09-29 (layoff filings and notices).
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Perceptive Advisors LLC | 7.9% | 1,304,846 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| Bvf Partners L P | 7.6% | 1,251,788 | SCHEDULE 13G, 2026-02-18 | 2026-02-10 |
| Affinity Asset Advisors, LLC | 6.5% | 1,069,519 | SCHEDULE 13G/A, 2026-05-14 | 2026-03-31 |
| BlackRock, Inc. | 6.4% | 1,065,366 | SCHEDULE 13G, 2026-07-30 | 2026-06-30 |
| 6.4% | 1,062,872 | SCHEDULE 13G, 2026-05-15 | 2026-02-11 | |
| Kynam Capital Management, LP | 5.27% | 0 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| Coastlands Capital LP | 5.14% | 852,669 | SCHEDULE 13G, 2026-11-09 | 2026-11-05 |
| The Vanguard Group | 4.87% | 4,115,250 | SCHEDULE 13G/A, 2025-07-29 | 2025-06-30 |
| Point72 Asset Management, L.P. | 1.4% | 237,827 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| Millennium Management LLC | 1.3% | 210,378 | SCHEDULE 13G/A, 2026-04-21 | 2026-03-31 |
| Suvretta Capital Management, LLC | 0% | 0 | SCHEDULE 13G/A, 2026-02-13 | 2025-12-31 |
| RA Capital Management, L.P. | 0% | 0 | SCHEDULE 13G/A, 2025-08-14 | 2025-06-30 |
Holding shares or following this stake? See who's behind Sutro Biopharma, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Sutro Biopharma, Inc. and the records around it.
Sutro Biopharma, Inc. elsewhere on the record
- Layoff notices Sep 2025
- Who owns it
Companies that share a holder
- Kynam Capital Management, LP also filed stake reports on 8 other companies: Celldex Therapeutics, Inc. (Aug 2026), CytomX Therapeutics, Inc. (Aug 2026), Vera Therapeutics, Inc. (Aug 2026)
- Affinity Asset Advisors, LLC also filed stake reports on 13 other companies: Amanat Acquisition Corp. (Aug 2026), Avalo Therapeutics, Inc. (Aug 2026), Equillium Inc. (Aug 2026)
- Samsara BioCapital, L.P. also filed stake reports on 14 other companies: PMV Pharmaceuticals, Inc. (Sep 2026), Eloxx Pharmaceuticals, Inc. (Aug 2026), RANI THERAPEUTICS HOLDINGS, INC. (May 2026)
Watch Sutro Biopharma, Inc.
Get an email when Sutro Biopharma, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Sutro Biopharma, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Sutro Biopharma, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Sutro Biopharma, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
20 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Perceptive Advisors LLC | 0 | 1,304,846 | 0 | 1,304,846 | SCHEDULE 13G/A, 2026-08-14 |
| Joseph Edelman | 0 | 1,304,846 | 0 | 1,304,846 | SCHEDULE 13G/A, 2026-08-14 |
| Perceptive Life Sciences Master Fund, Ltd. | 0 | 1,304,846 | 0 | 1,304,846 | SCHEDULE 13G/A, 2026-08-14 |
| BlackRock, Inc. | 1,052,565 | 0 | 1,065,366 | 0 | SCHEDULE 13G, 2026-07-30 |
| Coastlands Capital LP | 0 | 852,669 | 0 | 852,669 | SCHEDULE 13G, 2026-11-09 |
| Coastlands Capital Partners LP | 0 | 852,669 | 0 | 852,669 | SCHEDULE 13G, 2026-11-09 |
| Coastlands Capital GP LLC | 0 | 852,669 | 0 | 852,669 | SCHEDULE 13G, 2026-11-09 |
| Coastlands Capital LLC | 0 | 852,669 | 0 | 852,669 | SCHEDULE 13G, 2026-11-09 |
| Matthew D. Perry | 0 | 852,669 | 0 | 852,669 | SCHEDULE 13G, 2026-11-09 |
| Point72 Asset Management, L.P. | 0 | 237,827 | 0 | 237,827 | SCHEDULE 13G/A, 2026-08-14 |
| Point72 Capital Advisors, Inc. | 0 | 237,827 | 0 | 237,827 | SCHEDULE 13G/A, 2026-08-14 |
| Steven A. Cohen | 0 | 237,827 | 0 | 237,827 | SCHEDULE 13G/A, 2026-08-14 |
The latest filing identifies Sutro Biopharma, Inc. by CUSIP 869367201 and gives its principal executive office as 111 Oyster Point Blvd, South San Francisco, CA 94080 (SCHEDULE 13G, 2026-11-09).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-16 | BlackRock, Inc. | 2.5% | SCHEDULE 13G/A |
| 2025-07-29 | The Vanguard Group | 4.87% | SCHEDULE 13G/A |
| 2025-08-13 | Suvretta Capital Management, LLC | 7.7% | SCHEDULE 13G/A |
| 2025-08-14 | RA Capital Management, L.P. | 0% | SCHEDULE 13G/A |
| 2025-10-23 | Affinity Healthcare Fund, LP | 7.77% | SCHEDULE 13G |
| 2026-01-29 | Affinity Asset Advisors, LLC | 8.8% | SCHEDULE 13G/A |
| 2026-02-13 | Suvretta Capital Management, LLC | 0% | SCHEDULE 13G/A |
| 2026-02-13 | Suvretta Capital Management, LLC | 0% | SCHEDULE 13G/A |
| 2026-02-18 | Bvf Partners L P | 7.6% | SCHEDULE 13G |
| 2026-04-21 | Millennium Management LLC | 1.3% | SCHEDULE 13G/A |
| 2026-04-21 | Perceptive Advisors LLC | 5.4% | SCHEDULE 13G |
| 2026-05-01 | Point72 Asset Management, L.P. | 5.7% | SCHEDULE 13G |
| 2026-05-14 | Affinity Asset Advisors, LLC | 6.5% | SCHEDULE 13G/A |
| 2026-05-15 | Srinivas Akkaraju | 6.4% | SCHEDULE 13G |
| 2026-05-15 | Kynam Capital Management, LP | 5.27% | SCHEDULE 13G/A |
| 2026-07-30 | BlackRock, Inc. | 6.4% | SCHEDULE 13G |
| 2026-08-14 | Point72 Asset Management, L.P. | 1.4% | SCHEDULE 13G/A |
| 2026-08-14 | Perceptive Advisors LLC | 7.9% | SCHEDULE 13G/A |
| 2026-11-09 | Coastlands Capital LP | 5.14% | SCHEDULE 13G |
Questions about who owns Sutro Biopharma, Inc.
Who owns Sutro Biopharma, Inc.?
On this page, 7 holders' latest ownership filings report 5% or more of Sutro Biopharma, Inc.: Perceptive Advisors LLC (7.9%, Schedule 13G/A, filed 2026-08-14), Bvf Partners L P (7.6%, Schedule 13G, filed 2026-02-18), Affinity Asset Advisors, LLC (6.5%, Schedule 13G/A, filed 2026-05-14), BlackRock, Inc. (6.4%, Schedule 13G, filed 2026-07-30) and Srinivas Akkaraju (6.4%, Schedule 13G, filed 2026-05-15); 2 more are listed above.
Who are the largest shareholders of Sutro Biopharma, Inc.?
By the share each holder's latest filing reports, the largest holders of Sutro Biopharma, Inc. on this page are Perceptive Advisors LLC (7.9%), Bvf Partners L P (7.6%) and Affinity Asset Advisors, LLC (6.5%).
When did Perceptive Advisors LLC buy into Sutro Biopharma, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Perceptive Advisors LLC on this page is the Schedule 13G, filed 2026-04-21, reporting 5.4%; its latest, Schedule 13G/A filed 2026-08-14, reports 7.9%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 19 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for Sutro Biopharma, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.